Treatment of Helicobacter pylori infection

Current Opinion in Gastroenterology

Volumn 14, Issue 1, 1998, Pages 64-69

  Go, Mae F ^a   Fennerty, M Brian ^b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; BISMUTH SALICYLATE; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; RANITIDINE BISMUTH CITRATE; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; DYSPEPSIA; GASTRITIS; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; LYMPH FOLLICLE; PEPTIC ULCER; RECURRENT DISEASE; REVIEW; STANDARDIZATION; UNITED STATES;

EID: 0031963762     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199801000-00012     Document Type: Review

References (26)

1. Harford W, Lanza F, Arora A, Graham D, Haber M, Weissfeld A, Rose P, Siepman N: Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. Helicobacter 1996, 1:243-250.
2. Riff DS, Rose P, Haber M, Weissfeld A, Siepman N: Triple therapy with lansoprazole, clarithromycin, and amoxicillin for the cure of Helicobacter pylori infection: a short report Helicobacter 1996, 1:238-242. This study reflects the current perspective that cure of H. pylori infection will lead to significantly reduced recurrent peptic ulcers and the impact of antimicrobial resistance on cure rates. This study includes features that future clinical trials will need to assess, such as frequency of clarithromycin and metronidazole resistance in clinical isolates from their study population as part of efficacy analysis.
3. Axon AT, Ireland A, Smith MJ, Rooprams PD: Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1997, 11:81-87.
4. Labenz J, Beker JA, Dekker CP, Farley A, Klor HU, Jonsson A: Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. Aliment Pharmacol Ther 1997, 11:515-522. The clinical importance of this paper is that it demonstrates the poor efficacy and marked variability of results with OA. Therefore, this regimen should not be used in clinical practice.
5. Goddard AF, Spiller RC: Helicobacter pylori eradication in clinical practice: one-week low-dose triple therapy is preferable to classical bismuth based triple therapy. Aliment Pharmacol Ther 1996, 10:1009-1013.
6. Moshkowitz M, Konikoff FM, Peled Y, Brill S, Hallak A, Tiomny E, Santo M, Bujanover Y, Gilat T: One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. Aliment Pharmacol Ther 1996, 10:1015-1019.
7. Thijs JC, Van Zwet AA, Thijs WJ, Van der Wouden EJ, Kooy A: One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance. Aliment Pharmacol Ther 1997, 11:305-309.
8. Breuer T, Kim JG, Gurer IE, Graham DP, Osato M, Genta RM, Graham DY: Successful low-dose amoxycillin, metronidazole and omeprazole combination therapy in a population with a high frequency of metronidazole-resistant Helicobacter pylori. Aliment Pharmacol Ther 1997, 11:523-527.
9. Harris AW, Pryce DI, Gabe SM, Karim QN, Walker MM, Langworth H, Baron JH, Misiewicz JJ: Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. Aliment Pharmacol Ther 1996, 10:1005-1008.
10. Lazzaroni M, Bargiggia S, Porro GB: Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. Am J Gastroenterol 1997, 92:649-652.
11. Lim AG, Walker C, Chambers S, Gould SR: Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. Aliment Pharmacol Ther 1997, 11:537-540.
12. Laine L, Estrada R, Trujillo M, Fukanaga K, Neil G: Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996, 10:1029-1033. This paper sets the standard for reporting efficacy data both by per-protocol and intention-to-treat results. Additionally, it is the largest published US study of PPI-based triple therapy, with data also on treatment duration.
13. Labenz J, Tillenburg B, Weismuller J, Luetke A, Stolte M: Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. Aliment Pharmacol Ther 1997, 11:95-100.
14. Cammarota G, Tursi A, Papa A, Montalto M, Veneto G, Cuoco L, Fedeli G, Gasbarrini G: Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. Aliment Pharmacol Ther 1996, 10:997-1000. This study highlights an important clinical issue. Substitution of antimicrobial agents within a class usually leads to a decrease in regimen efficacy. The only exception to this is with PPIs, which are interchangeable.
15. Vautier G, Scott BB: A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice. Aliment Pharmacol Ther 1997, 11:107-108.
16. Kung NN, Sung JJ, Yuen NW, Ng PW, Wong KC, Chung ECH, Lim BH, Choi CH, Li TH, Ma HC, Kwok SPY: Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy. Am J Gastroenterol 1997, 92:438-441.
17. de Boer WA, van Etten RJ, Schade RW, Ouwehand ME, Schneeberger PM, Van Unnik AJM, Tytgat GNJ: One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1997, 11:109-112.
18. Ching CK, Leung KP, Yung RWH, Lam SK, Wong BCY, Lai KC, Lai CL: Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer patients and normal controls in Hong Kong. Gut 1996, 38:675-678.
19. Lerang F, Moun B, Haug JB, Tolas P, Breder O, Aubert E, Hoie O, Soberg T, Flaaten B, Farup P, Berge: Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? Am J Gastroenterol 1997, 92:248-253. This large multicenter study of patients with peptic ulcer demonstrates that H. pylori metronidazole resistance may significantly reduce cure rates. This study also shows that clarithromycin can overcome metronidazole resistance to yield highly effective regimens.
20. Megraud F: Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997, 11(suppl 1):43-53. A nice overview of antimicrobial resistance, methodologies for antimicrobial susceptibility testing, and their mechanisms in H. pylori.
21. Lee J, O'Morain C: Consensus or confusion: a review of existing national guidelines of Helicobacter pylori-related disease. Eur J Gastroenterol Hepatol 1997, 9:527-531.
22. Laheij RJ, Jansen JBMJ, van de Lisdonk EH, Severens JL, Verbeek ALM: Symptom improvement through eradication of Helicobacter pylori in patients with non-ulcer dyspepsia [review]. Aliment Pharmacol Ther 1996, 10:843-850.
23. Gilvarry J, Buckley MJ, Beattie S, Hamilton H, O'Morain CA: Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. Scand J Gastroenterol 1997, 32:535-540. Well-designed study indicating that treating patients with nonulcer dyspepsia may improve their clinical outcome (see Ofman et al., Ann Intern Med 1997, 126:280-291).
24. Gilvarry J, Buckley MJ, Beattie S, Hamilton H, O'Morain CA: Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. Scand J Gastroenterol 1997, 32:535-540. Well-designed study indicating that treating patients with nonulcer dyspepsia may improve their clinical outcome (see Ofman et al., Ann Intern Med 1997, 126:280-291).
25. Ofman JJ, Ofman JJ, Etachason J, Fullerton S, Kahn KI, Soll AH: Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med 1997, 126:280-291. This economic model of a dyspeptic population suggests that treatment of this population may also be cost-effective (see also Gilvarry et al., Scand J Gastroenterol 1997, 32:535-540).
26. Ofman JJ, Ofman JJ, Etachason J, Fullerton S, Kahn KI, Soll AH: Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med 1997, 126:280-291. This economic model of a dyspeptic population suggests that treatment of this population may also be cost-effective (see also Gilvarry et al., Scand J Gastroenterol 1997, 32:535-540).